Drug intelligence / Profile preview

NasalGuard

Development stage
Unknown
Lead developer
Trutek
Modality
Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems
Administration
Topical
01

Overview

NasalGuard is a topical, non-systemic electrostatic gel designed to prevent the inhalation of airborne particles, including allergens (pollen, pet dander, dust mites), pollutants, and pathogens (viruses and bacteria). Developed by Trutek Corp, the product is applied as a thin layer around the nostrils and above the upper lip. It functions by creating a localized electrostatic field with a positive charge that attracts and traps negatively charged airborne particles, or repels similarly charged ones, before they can enter the nasal passages. This physical barrier mechanism helps reduce the viral or allergen load reaching the respiratory system, making it a preventative tool for allergic rhinitis and respiratory infections. As a drug-free and non-invasive formulation, it is often regulated as a medical device rather than a pharmacological agent.

Brand names
NasalGuardNasalGuard Airborne Particle Blocker
Other names
NasalGuard Allergen Block

Beyond the preview

Go deeper on NasalGuard.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on NasalGuard.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call